What's in AGUNCO Obstetrics and Gynecology Centre's pipeline?

AGUNCO Obstetrics and Gynecology Centre has 4 drugs in our index: 4 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with AGUNCO Obstetrics and Gynecology Centre's portfolio?

Top competitors by shared drug class: Azienda USL Modena, Bezmialem Vakif University, Central Jutland Regional Hospital, D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology, Dunamenti REK Istenhegyi IVF Center.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/agunco-obstetrics-and-gynecology-centre.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

AGUNCO Obstetrics and Gynecology Centre — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AGUNCO Obstetrics and Gynecology Centre pipeline: 4 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Recombinant FSH (rFSH)	Recombinant FSH (rFSH)	marketed	Gonadotropin	FSH receptor (FSHR)	Reproductive Medicine / Fertility
Drospirenone Ethinyl estradiol	Drospirenone Ethinyl estradiol	marketed
Folic acid, vit B12	Folic acid, vit B12	marketed	Vitamin supplement combination		Obstetrics and Gynecology / Nutritional supplementation
Drospirenone Ethinyl estradiol Myo-inositol	Drospirenone Ethinyl estradiol Myo-inositol	marketed	Oral contraceptive with insulin sensitizer	Progesterone receptor, estrogen receptor, inositol signaling pathway	Gynecology / Reproductive Health

Therapeutic area mix

Gynecology / Reproductive Health · 1
Obstetrics and Gynecology / Nutritional supplementation · 1
Reproductive Medicine / Fertility · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Azienda USL Modena · 1 shared drug class
Bezmialem Vakif University · 1 shared drug class
Central Jutland Regional Hospital · 1 shared drug class
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology · 1 shared drug class
Dunamenti REK Istenhegyi IVF Center · 1 shared drug class
El Shatby University Hospital for Obstetrics and Gynecology · 1 shared drug class
Fundación Santiago Dexeus Font · 1 shared drug class
Ain Shams Maternity Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for AGUNCO Obstetrics and Gynecology Centre:

Cite this brief

Drug Landscape (2026). AGUNCO Obstetrics and Gynecology Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/agunco-obstetrics-and-gynecology-centre. Accessed 2026-05-17.